2023
791-P: Comparing the Real-World Effects of Once-Weekly GLP-1 RAs and DPP-4 Inhibitors on Ischemic Stroke and Myocardial Infarction in Individuals with T2D and ASCVD
TAN X, LIANG Y, RAJPURA J, YEDIGAROVA L, NOONE J, XIE L, DE HAVENON A. 791-P: Comparing the Real-World Effects of Once-Weekly GLP-1 RAs and DPP-4 Inhibitors on Ischemic Stroke and Myocardial Infarction in Individuals with T2D and ASCVD. Diabetes 2023, 72 DOI: 10.2337/db23-791-p.Peer-Reviewed Original ResearchAtherosclerotic cardiovascular diseaseGLP-1 RAsMyocardial infarctionDPP-4iIschemic strokeCardiovascular eventsNovo NordiskGlucagon-like peptide-1 receptor agonistsWeekly glucagon-like peptide-1 receptor agonistMajor adverse cardiovascular eventsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsRisk of MINew adult usersAdverse cardiovascular eventsRetrospective cohort studyPeptidase-4 inhibitorsDPP-4 inhibitorsType 2 diabetesReal-world evidenceDrug discontinuationBaseline characteristicsCohort studyOptum ClinformaticsReceptor agonist
2021
Cilostazol for Secondary Stroke Prevention
de Havenon A, Sheth KN, Madsen TE, Johnston KC, Turan TN, Toyoda K, Elm JJ, Wardlaw JM, Johnston SC, Williams OA, Shoamanesh A, Lansberg MG. Cilostazol for Secondary Stroke Prevention. Stroke 2021, 52: e635-e645. PMID: 34517768, PMCID: PMC8478840, DOI: 10.1161/strokeaha.121.035002.Peer-Reviewed Original ResearchConceptsSecondary stroke preventionStroke preventionDouble-blind placebo-controlled randomized trialLargest secondary stroke prevention trialSecondary stroke prevention trialsPlacebo-controlled randomized trialStroke Prevention TrialTreatment of claudicationOpen-label designNoncardioembolic ischemic strokePeripheral arterial diseaseLong-term treatmentOnset of benefitDays of treatmentEuropean Medicines AgencyCognitive outcome dataMillions of patientsPremature trial terminationDrug discontinuationMajor bleedingGastrointestinal symptomsStroke recurrenceIschemic strokeNoncardioembolic strokeSecondary prevention